Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Rhea-AI Summary

Harrow (HROW) has announced a strategic partnership with Cencora (COR) to launch the 'Harrow Cares' program, aimed at improving accessibility and affordability of IHEEZO® and TRIESENCE® for retina specialists and their patients. The program offers comprehensive support services through a state-of-the-art patient support hub.

The initiative includes multiple key features: streamlined enrollment through various channels, real-time benefit verifications for rapid treatment access, flexible affordability options including commercial copay assistance with patients paying as little as $0, and ongoing support services including patient welcome calls and prior authorization denial assistance.

This partnership represents Harrow's strategic focus on expanding its presence in the U.S. retina market and demonstrates the company's commitment to improving healthcare accessibility while driving better patient outcomes.

Positive

• Strategic partnership with major pharmaceutical solutions provider Cencora
• Potential revenue growth through improved product accessibility
• Enhanced market penetration in U.S. retina segment
• Implementation of $0 copay program potentially increasing product adoption

Negative

• None.

Insights

Healthcare Market Analyst

The launch of Harrow Cares through the Cencora partnership represents a sophisticated market access strategy that could significantly impact Harrow's commercial success in the competitive ophthalmology market. The program addresses three critical barriers to treatment adoption: administrative burden, insurance verification and patient affordability.

The partnership with Cencora (formerly AmerisourceBergen) is particularly strategic as they possess extensive infrastructure and expertise in pharmaceutical distribution and patient support services. Their PXConnect technology integration capability suggests seamless integration with existing healthcare IT systems, potentially driving higher adoption rates among practices.

The program's comprehensive approach includes several revenue-driving mechanisms:

• The streamlined enrollment and real-time benefit verification can accelerate the treatment initiation process, potentially reducing the typical 2-3 week insurance approval timeline to same-day in many cases
• The commercial copay assistance program, offering $0 out-of-pocket costs for eligible patients, could significantly expand the addressable market
• The product replacement program reduces financial risk for practices, potentially encouraging broader stock holding and usage

This initiative particularly strengthens Harrow's position in the U.S. retina market, where complex reimbursement processes often create barriers to adoption of new treatments. The timing is strategic, as it coincides with growing demand for innovative ophthalmic solutions and increasing pressure on healthcare providers to improve operational efficiency.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSE: COR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their staff, and patients. Through a state-of-the-art patient support services hub, Harrow Cares ensures seamless enrollment, rapid access to therapy, and personalized support, enabling retina providers to confidently utilize IHEEZO® and TRIESENCE® in their practices.

Cencora, a global leader in pharmaceutical solutions, provides comprehensive solutions to facilitate and optimize market access to therapies. With services ranging from real-time benefit verifications to flexible affordability options and product assurance programs, Cencora is uniquely positioned to facilitate and optimize patient care for therapies like IHEEZO and TRIESENCE.

“We are thrilled to collaborate with Cencora on the launch of our ‘Harrow Cares’ program,” said Mark L. Baum, Chief Executive Officer of Harrow. “This partnership reflects our shared commitment to addressing one of the most critical challenges in healthcare – ensuring that life‑changing medications are both accessible and affordable. The Harrow Cares initiative underscores Harrow’s unwavering dedication to creating meaningful solutions that empower patients, reduce barriers to treatment, and drive better health outcomes. Furthermore, this milestone highlights our strategic focus on expanding and solidifying Harrow’s presence in the U.S. retina market, a key area of growth and innovation for our company. We look forward to working closely with Cencora to advance innovative ophthalmic solutions that enhance patient care and improve access to vital treatments.”

Key features of the Harrow Cares program include:

• Streamlined Enrollment: Providers can enroll via multiple channels, including phone, a dedicated provider portal, or PXConnect technology integration.
• Rapid Access to Therapy: Services provide real-time benefit verifications, enabling retina specialists to quickly verify patient benefits and secure timely access to treatment.
• Flexible Affordability: Includes an in-house commercial copay assistance program, patient assistance options, and referrals to third-party charitable foundations, allowing patients to pay as little as $0.
• Assurance and Ongoing Support: Additional features include patient welcome calls, annual reverification support, escalation for prior authorization denials, and assurance through product replacement programs.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward‑looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250127616869/en/

Jamie Webb

Director of Communications and Investor Relations

jwebb@harrowinc.com

615-733-4737

Source: Harrow, Inc.

FAQ

What is the Harrow Cares program launched by HROW in partnership with Cencora?

Harrow Cares is a comprehensive patient support program that provides access and affordability services for IHEEZO® and TRIESENCE®, including streamlined enrollment, real-time benefit verification, and flexible payment options allowing patients to pay as little as $0.

How does the HROW partnership with Cencora benefit retina specialists?

The partnership provides retina specialists with multiple enrollment channels, real-time benefit verifications, and streamlined access to treatments, making it easier to prescribe and administer IHEEZO® and TRIESENCE® to their patients.

What payment assistance options are available through Harrow Cares for HROW products?

The program offers commercial copay assistance, patient assistance options, and referrals to third-party charitable foundations, enabling patients to access treatments for as little as $0.

How does the Harrow Cares program impact HROW's market strategy?

The program represents HROW's strategic focus on expanding its presence in the U.S. retina market, aiming to enhance patient care access and drive better health outcomes through improved product accessibility.